📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
59 announcements match the current filters (relevance ≥ 5).
Alembic Pharma Appoints Ramesh Juneja as Senior Management Personnel for India Business
Alembic Pharmaceuticals has designated Mr. Ramesh Juneja as Senior Management Personnel effective June 1, 2026. Mr. Juneja, currently the EVP of Human Health (Sales and Marketing) for the India Business, brings over 30 years of industry experience. His background includes significant leadership roles at top-tier companies like Sun Pharma and Cipla. This move aims to leverage his expertise in driving business growth and market expansion within the competitive Indian pharmaceutical landscape.
Key Highlights
Appointment of Mr. Ramesh Juneja as Senior Management Personnel effective June 1, 2026
Over 30 years of experience in pharma sales and marketing across acute and chronic segments
Former leadership roles at Sun Pharmaceutical Industries, Cipla, and Reliance Retail (Netmeds)
Educational background includes an MBA from Symbiosis and executive programs at ISB and NUS
👀 What to Watch
This appointment strengthens the domestic leadership; investors should monitor for improved execution in the India business. No immediate action is required other than tracking performance metrics.
Alembic Pharma Receives USFDA Approval for Levothyroxine Tablets (Market Size: $1.87 Billion)
Alembic Pharmaceuticals has received final USFDA approval for its ANDA for Levothyroxine Sodium Tablets, a generic version of AbbVie's Synthroid. The approval covers 12 different strengths ranging from 25 mcg to 300 mcg, targeting a massive market estimated at US$ 1,869 million for the 12 months ending March 2026. This approval marks a significant addition to the company's US portfolio, which now includes 220 final ANDA approvals. The drug is used for treating hypothyroidism and managing certain types of thyroid cancer.
Key Highlights
Final USFDA approval received for Levothyroxine Sodium Tablets in 12 different dosage strengths.
Target market size for the product is estimated at US$ 1,869 million annually as of March 2026.
Product is therapeutically equivalent to the reference listed drug Synthroid by AbbVie, Inc.
Alembic now holds a cumulative total of 239 ANDA approvals, including 220 final approvals.
The medication is indicated for hypothyroidism replacement therapy and thyroid cancer management.
👀 What to Watch
This is a high-impact approval given the large addressable market size of nearly $1.9 billion. Investors should monitor the company's commercial launch timeline and market share gains in the US generic space.
Alembic Pharma Q4 FY26: FY PAT Grows 16% to ₹675 Cr; Targets Double-Digit Growth in FY27
Alembic Pharmaceuticals reported a steady Q4 FY26 with revenue of ₹1,838 crores, up 4% YoY, while full-year revenue grew 10%. The company achieved a full-year PAT of ₹675 crores, a 16% increase, driven by international market expansion and specialty therapies in India. Management has provided a positive outlook for FY27, targeting low double-digit top-line growth and planning R&D investments of ₹750-800 crores. Key growth drivers include the scaling of the US branded business and improved capacity utilization at the F2 and F3 facilities.
Key Highlights
Q4 FY26 revenue rose 4% to ₹1,838 crores with core EBITDA margins improving to 25%.
Full-year FY26 PAT increased 16% to ₹675 crores, supported by a 20% growth in Ex-US international markets.
R&D spend for FY27 is projected at ₹750-800 crores, focusing on high-value NCE-1 and Day 1 molecules.
The F3 ophthalmic line is currently at full capacity, prompting a planned expansion to meet demand.
FY27 Capex is guided at ₹300-350 crores, primarily for debottlenecking and replacement activities.
👀 What to Watch
Investors should focus on the successful scale-up of the US branded business and the margin impact of high-value R&D filings. The company's shift toward execution-led growth and improved facility utilization provides a solid foundation for medium-term gains.
Alembic Pharma FY26 Net Profit Rises 27% to ₹640 Cr; Dividend Hiked to ₹12 Per Share
Alembic Pharmaceuticals reported a steady 10.2% growth in annual standalone revenue to ₹6,651.38 crore for FY26. The standalone net profit saw a significant 27.3% increase to ₹640.42 crore, though this was aided by a one-time deferred tax credit of ₹100.27 crore in the final quarter. Operating margins improved to 16.82% from 15.74% year-on-year, reflecting better operational efficiency despite exceptional costs. The board has rewarded shareholders by increasing the dividend to ₹12 per share, up from ₹11 in the previous year.
Key Highlights
Annual Revenue from Operations grew 10.2% YoY to ₹6,651.38 crore.
Standalone Net Profit increased by 27.3% to ₹640.42 crore for the full year.
Board recommended a higher dividend of ₹12 per equity share (600% of face value).
Operating margins improved to 16.82% compared to 15.74% in the previous fiscal.
Exceptional items included a ₹48.64 crore impact from new Labour Codes and an ₹18.35 crore write-down for the Sikkim facility.
👀 What to Watch
The company shows healthy revenue growth and margin expansion, coupled with a higher dividend payout. Investors should maintain a positive outlook but monitor the impact of the new Labour Codes on future employee costs.
Alembic Pharma Passes Brazil's ANVISA GMP Inspection with Zero Observations for Karakhadi Facility
Alembic Pharmaceuticals has successfully cleared a Good Manufacturing Practices (GMP) inspection by the Brazilian Health Regulatory Agency (ANVISA) for its API-III facility at Karakhadi. The inspection, conducted from May 11 to May 15, 2026, concluded with zero observations, reflecting high compliance standards. This regulatory approval is significant as it allows the company to supply multiple Active Pharmaceutical Ingredients (APIs) to the Brazilian market. Such clearances are critical for maintaining and expanding the company's international revenue streams and reducing regulatory risk.
Key Highlights
Successful completion of ANVISA (Brazil) GMP inspection at the Karakhadi API-III facility.
The audit resulted in zero observations, indicating full compliance with regulatory standards.
Inspection was conducted over a five-day period from May 11, 2026, to May 15, 2026.
The clearance facilitates the export of multiple APIs to the Brazilian pharmaceutical market.
👀 What to Watch
Investors should view this as a positive development that strengthens the company's export potential in Latin America. The zero-observation report mitigates regulatory concerns and supports long-term growth in the API segment.
Alembic Pharma Recommends Rs 12 Dividend; FY26 Net Profit Rises 27% to Rs 640 Cr
Alembic Pharmaceuticals reported a strong financial performance for FY26, with annual revenue growing 10.2% YoY to Rs 6,651.38 crore. Net profit for the year surged by 27.3% to reach Rs 640.42 crore, driven by improved operating margins which rose to 16.82%. Reflecting this growth, the Board has recommended an increased dividend of Rs 12 per share (600% of face value). The company also maintained a healthy balance sheet, reducing its debt-equity ratio to 0.20.
Key Highlights
Recommended a final dividend of Rs 12 per equity share for FY 2025-26, up from Rs 11 in FY 2024-25.
Annual Revenue from Operations increased to Rs 6,651.38 crore from Rs 6,032.63 crore in the previous year.
Net Profit for the financial year grew to Rs 640.42 crore compared to Rs 503.11 crore in FY25.
Operating Margin improved to 16.82% for FY26, up from 15.74% in the prior year.
Exceptional items included a Rs 48.64 crore provision for new Labour Codes and a Rs 18.35 crore write-down for the Sikkim facility.
👀 What to Watch
Investors should take note of the steady revenue growth and significant margin expansion, which supports the higher dividend payout. The company's low leverage and consistent profitability make it a stable pick in the pharmaceutical sector.
Alembic Pharma Q4 FY26: Net Profit Jumps 29% to Rs 203 Cr; US Revenue Grows 11%
Alembic Pharmaceuticals reported a strong bottom-line performance for Q4 FY26, with Net Profit surging 29% YoY to Rs 203 Cr despite a modest 4% growth in total revenue to Rs 1,848 Cr. The US formulation segment was a major growth driver, increasing 11% to Rs 564 Cr, supported by six new launches and a strategic entry into the US branded market with Pivya. The India branded business grew 4% to Rs 568 Cr, led by specialty segments like Gynaecology and Gastrology. Pre-R&D EBITDA margins remained healthy at 25%, reflecting disciplined cost management and operational efficiency.
Key Highlights
Net Profit (PAT) increased 29% YoY to Rs 203 Cr for the quarter ended March 31, 2026.
US Formulation revenue grew 11% to Rs 564 Cr, supported by 6 new product launches and 4 ANDA approvals.
Pre-R&D EBITDA rose 8% YoY to Rs 455 Cr with a robust margin of 25%.
India Branded Business revenue reached Rs 568 Cr, marking a 4% YoY growth.
Strategic entry into the US Branded Pharmaceuticals market with the launch of Pivya for uUTIs.
👀 What to Watch
Investors should view the significant margin improvement and the strategic pivot into the US branded specialty market as positive long-term catalysts. Monitor the commercial traction of Pivya and the sustainability of the 25% pre-R&D EBITDA margins in upcoming quarters.
Alembic Pharma Q4 PAT Jumps 29% to ₹2.03 Bn; US Sales Grow 11%
Alembic Pharmaceuticals reported a steady Q4 FY26 with revenue growing 4% YoY to INR 18.48 billion, while Net Profit surged 29% to INR 2.03 billion. The US formulation business was a key driver, growing 11% YoY, supported by 15 new product launches during the fiscal year. The India branded business grew 4%, though the Animal Health segment within it showed robust 27% growth. Despite a 39% spike in R&D spending to 11% of revenue, the company maintained a healthy pre-R&D EBITDA margin of 25%.
Key Highlights
Reported PAT for Q4 FY26 increased 29% YoY to INR 2.03 billion.
US Formulation revenue grew 11% YoY to INR 5.64 billion, driven by new launches and market share gains.
Animal Health business showed strong momentum with 27% YoY growth reaching INR 1.24 billion in Q4.
R&D expenditure rose significantly by 39% YoY to INR 2.09 billion, representing 11% of total sales.
Full-year FY26 revenue reached INR 73.45 billion, a 10% increase over the previous fiscal year.
👀 What to Watch
Investors should monitor the ramp-up of the newly launched US branded product 'Pivya' and the impact of high R&D investments on future margins. The company's strong performance in the US and Animal Health segments offsets the relatively modest growth in the domestic branded business.
Alembic Pharma FY26 Net Profit Rises 27% to ₹640 Cr; Dividend Hiked to ₹12 Per Share
Alembic Pharmaceuticals reported a robust performance for the financial year ended March 31, 2026, with annual revenue growing 10.2% to ₹6,651.38 crore. Net profit for the full year surged by 27.3% to ₹640.42 crore, aided by improved operating margins and a significant deferred tax credit of ₹100.27 crore. The company also announced an increased dividend of ₹12 per share, reflecting strong cash flow and management confidence. Despite exceptional charges of ₹66.99 crore related to labor codes and facility write-downs, the overall financial health remains stable with a low debt-equity ratio of 0.20.
Key Highlights
Annual revenue from operations increased to ₹6,651.38 crore from ₹6,032.63 crore in FY25.
Net profit for FY26 grew to ₹640.42 crore, up from ₹503.11 crore in the previous year.
Operating margins improved to 16.82% in FY26 compared to 15.74% in FY25.
Recommended a dividend of ₹12 per equity share (600%) for FY26, up from ₹11 in FY25.
Recognized a one-time deferred tax credit of ₹100.27 crore in Q4 FY26 following tax reassessments.
👀 What to Watch
Investors should take note of the consistent margin expansion and the management's decision to increase the dividend payout. The stock remains a strong candidate for long-term portfolios given its operational efficiency and healthy balance sheet.
Alembic Pharma FY26 Net Profit Rises 27% to ₹640 Cr; Recommends ₹12 Dividend
Alembic Pharmaceuticals reported a strong financial performance for FY26, with standalone revenue growing 10.2% YoY to ₹6,651.38 crore. Net profit for the full year increased significantly by 27.3% to ₹640.42 crore, supported by improved operating margins and a one-time deferred tax credit of ₹100.27 crore. The company has rewarded shareholders by recommending an increased dividend of ₹12 per share (600%). Despite exceptional charges of ₹48.64 crore related to new labour codes and an ₹18.35 crore write-down for its Sikkim facility, the balance sheet remains healthy with a low debt-equity ratio of 0.20.
Key Highlights
FY26 Standalone Revenue increased 10.2% YoY to ₹6,651.38 crore from ₹6,032.63 crore.
Annual Net Profit grew 27.3% to ₹640.42 crore, while Q4 profit jumped to ₹243.07 crore.
Operating margins improved to 16.82% in FY26 compared to 15.74% in FY25.
Board recommended a higher dividend of ₹12 per share for FY26 versus ₹11 in the previous year.
Exceptional items included a ₹48.64 crore provision for labour codes and an ₹18.35 crore write-down on Sikkim assets.
👀 What to Watch
Investors should take note of the consistent margin expansion and the company's ability to grow profits despite exceptional regulatory and facility-related charges. The increased dividend payout and low leverage make it a stable long-term holding in the pharmaceutical space.
Alembic Pharma Receives USFDA EIR for Karakhadi Injectable Facility (F-III)
Alembic Pharmaceuticals has successfully received the Establishment Inspection Report (EIR) from the USFDA for its Injectable Facility (F-III) located at Karakhadi. This report follows a regulatory inspection conducted between February 9 and February 18, 2026. The receipt of an EIR indicates that the USFDA has concluded its audit and the facility is deemed compliant with manufacturing standards. This clearance is a significant milestone for the company's injectable portfolio and future product launches in the US market.
Key Highlights
Received Establishment Inspection Report (EIR) from USFDA on May 13, 2026
Inspection conducted at Karakhadi Injectable Facility (F-III) from Feb 9 to Feb 18, 2026
Successful closure of the regulatory audit for this critical manufacturing site
Clears the path for potential new product approvals from the F-III facility
👀 What to Watch
Investors should view this as a positive regulatory development that reduces compliance risk for the company's injectable segment. Maintain a positive outlook on the stock as this clearance supports future revenue growth from the US market.
Alembic Pharma Receives USFDA Tentative Approval for Darolutamide (Market Size: $3.15 Billion)
Alembic Pharmaceuticals has received tentative approval from the USFDA for Darolutamide Tablets, 300 mg, a generic version of Bayer's Nubeqa. The drug is indicated for treating adult patients with various forms of prostate cancer, including non-metastatic and metastatic castration-sensitive prostate cancer. This approval targets a significant market, with IQVIA estimating the annual market size at approximately US$ 3,155 million for the period ending March 2026. This milestone strengthens Alembic's oncology portfolio and brings its total USFDA ANDA approvals to 238.
Key Highlights
Received USFDA tentative approval for Darolutamide Tablets, 300 mg, used in prostate cancer treatment.
Target market size for the drug is estimated at US$ 3,155 million for the twelve months ending March 2026.
The product is therapeutically equivalent to the reference listed drug Nubeqa by Bayer HealthCare Pharmaceuticals.
Alembic now has a cumulative total of 238 ANDA approvals, including 219 final and 19 tentative approvals.
👀 What to Watch
This is a positive development for Alembic's US generic pipeline in the high-value oncology segment. Investors should monitor the transition from tentative to final approval and the subsequent commercial launch timeline.
Alembic Pharma Receives USFDA Final Approval for Fingolimod Capsules (Market Size $145M)
Alembic Pharmaceuticals has secured final USFDA approval for Fingolimod Capsules (0.5 mg), which is the generic version of Novartis' Gilenya. The drug is indicated for treating relapsing forms of multiple sclerosis in patients aged 10 and older. According to IQVIA data, the market size for this product is estimated at US$ 145 million for the twelve months ending December 2025. This approval strengthens Alembic's US portfolio, bringing their total cumulative ANDA approvals to 237.
Key Highlights
Final USFDA approval for Fingolimod Capsules, 0.5 mg, a generic equivalent to Gilenya.
Target market size estimated at US$ 145 million for the 12-month period ending December 2025.
The drug is used for treating relapsing forms of multiple sclerosis (MS) in adults and children.
Alembic now has a total of 237 ANDA approvals, consisting of 219 final and 18 tentative approvals.
👀 What to Watch
This approval is a positive development for Alembic's US generics pipeline and should contribute to revenue growth. Investors should monitor the company's execution and market share capture in this competitive $145 million segment.
Alembic Pharma Incorporates Wholly-Owned Subsidiary in Germany with EUR 25,000 Share Capital
Alembic Pharmaceuticals has announced the incorporation of a 100% wholly-owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany. The new entity is established with an initial share capital of EUR 25,000, consisting of 25,000 shares at EUR 1.00 each. This strategic move is designed to explore new business opportunities and establish a direct presence for the promotion, sale, and distribution of pharmaceutical products in the German market. As a newly formed entity, it currently has nil turnover and is yet to commence commercial operations.
Key Highlights
Incorporation of 100% wholly-owned subsidiary 'Alembic Pharmaceuticals GmbH' in Germany.
Initial share capital set at EUR 25,000 divided into 25,000 shares of EUR 1.00 each.
Objective is to promote, sell, and distribute pharmaceutical products in the European geography.
The entity is a fresh incorporation with zero turnover as of the announcement date.
👀 What to Watch
Investors should view this as a positive long-term strategic move to strengthen the company's footprint in the European market. Monitor future updates regarding product registrations and revenue contributions from this new German entity.
Alembic Pharma Incorporates New Subsidiary in Philippines with 12M PHP Share Capital
Alembic Pharmaceuticals has incorporated a 99.99% owned subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The new entity has an initial share capital of 12,000,000 Philippine Pesos, divided into 1.2 million shares. This strategic move is intended to explore new business opportunities and facilitate the promotion, sale, and distribution of pharmaceutical products in the Philippine market. As a newly formed entity, it has not yet commenced business operations and currently reports nil turnover.
Key Highlights
Incorporated a 99.99% owned subsidiary named Alembic Lifesciences Philippines Inc.
Initial share capital of 12,000,000 Philippine Pesos (approx. 1.2 million shares of 10 PHP each).
Objective is to promote, sell, and distribute pharmaceutical products in the Philippines.
The subsidiary is currently in the pre-operational stage with zero turnover reported.
👀 What to Watch
Investors should view this as a positive step toward geographic diversification. Monitor future earnings calls for updates on the subsidiary's operational rollout and its impact on the company's international revenue.
Alembic Pharma Receives USFDA Final Approval for Methotrexate Injection
Alembic Pharmaceuticals has received final USFDA approval for its Methotrexate Injection USP, which is therapeutically equivalent to Hospira's reference drug. The injection is a folate analog metabolic inhibitor used to treat various cancers, rheumatoid arthritis, and severe psoriasis. This approval marks a significant addition to Alembic's US portfolio, targeting both oncology and autoimmune segments. With this, the company's cumulative USFDA approvals have reached 236, including 218 final approvals.
Key Highlights
Received final USFDA approval for Methotrexate Injection USP in 50 mg/2 mL and 1g/40 mL strengths
Product is indicated for multiple neoplastic diseases including Leukemia, Breast Cancer, and Head/Neck Cancer
Also approved for treating rheumatoid arthritis and severe psoriasis
Cumulative USFDA approvals now stand at 236 (218 final and 18 tentative approvals)
👀 What to Watch
This approval strengthens Alembic's US generic pipeline in high-value therapeutic areas like oncology and immunology. Investors should monitor the company's commercial launch timeline and market share gains in these segments.
Alembic Pharma Re-appoints Pranav Amin as Managing Director for 5-Year Term
Alembic Pharmaceuticals has officially implemented the re-appointment of Mr. Pranav Amin as Managing Director, effective April 1, 2026. This follows the shareholder approval previously granted during the 15th Annual General Meeting held in August 2025. Mr. Amin, who leads the company's International Business, will serve a five-year term and is not liable to retire by rotation. The move ensures leadership continuity as the company focuses on international expansion and research-driven growth.
Key Highlights
Mr. Pranav Amin re-appointed as Managing Director for a 5-year term starting April 1, 2026.
The appointment was previously approved by shareholders at the 15th AGM on August 5, 2025.
Mr. Amin is responsible for the International Business division, focusing on global R&D and manufacturing.
The appointee is not liable to retire by rotation and is not debarred by any SEBI order.
Mr. Amin is part of the promoter family, being the son of Chairman Chirayu Amin.
👀 What to Watch
Investors should view this as a routine management continuity event that maintains the current strategic direction of the company's international operations. No immediate portfolio action is required based solely on this announcement.
Alembic Pharma: Chirayu Amin Appointed Executive Chairman for 5 Years; Steps Down as CEO
Alembic Pharmaceuticals has announced that Mr. Chirayu Amin has transitioned to the role of Executive Chairman for a five-year term starting April 1, 2026. He has simultaneously relinquished his position as the Chief Executive Officer (CEO) following the completion of his previous tenure. This move, which was approved by shareholders in August 2025, ensures leadership stability within the promoter family. Mr. Amin is the father of the company's current Managing Directors, Pranav and Shaunak Amin, indicating a clear succession and continuity plan.
Key Highlights
Mr. Chirayu Amin appointed as Executive Chairman for a 5-year term effective April 1, 2026.
Relinquished the position of Chief Executive Officer (CEO) as of March 31, 2026.
The transition was previously approved by shareholders at the 15th AGM held on August 5, 2025.
Mr. Amin will not be liable to retire by rotation during his new tenure as Executive Chairman.
👀 What to Watch
This is a planned leadership transition that ensures continuity within the promoter-led management. Investors should view this as a routine administrative update with no immediate impact on the company's operational strategy.
Alembic Pharma Re-appoints Pranav Amin as Managing Director for 5-Year Term
Alembic Pharmaceuticals has officially re-appointed Mr. Pranav Amin as Managing Director for a five-year term, effective from April 1, 2026. This move follows the shareholder approval previously granted at the 15th Annual General Meeting in August 2025. Mr. Amin, who heads the International Business, has been a key driver of the company's global expansion and R&D-led growth. The re-appointment ensures leadership continuity in critical business segments for the next half-decade.
Key Highlights
Re-appointment of Mr. Pranav Amin as Managing Director for a 5-year tenure starting April 1, 2026.
The appointee is not liable to retire by rotation during this term.
Mr. Amin leads the International Business division, focusing on R&D and high-quality manufacturing.
The appointment was ratified by shareholders during the 15th AGM held on August 5, 2025.
👀 What to Watch
Investors should view this as a positive sign of management stability and continuity in the company's international growth strategy. No immediate portfolio action is required as this is a planned leadership extension.
Alembic Pharma Receives USFDA Final Approval for Paroxetine ER Tablets (12.5 mg)
Alembic Pharmaceuticals has received final USFDA approval for its supplemental Abbreviated New Drug Application (sANDA) for Paroxetine Extended-Release Tablets, 12.5 mg. This product is therapeutically equivalent to Paxil CR Tablets and is used to treat major depressive and anxiety disorders. This approval strengthens Alembic's US portfolio, bringing its cumulative total to 235 ANDA approvals, including 216 final approvals. The approval allows the company to expand its presence in the central nervous system (CNS) therapeutic segment in the US market.
Key Highlights
Received final USFDA approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
Product is therapeutically equivalent to the reference listed drug Paxil CR Tablets (Apotex Inc.)
Indicated for Major depressive disorder (MDD), Panic disorder (PD), and Social anxiety disorder (SAD)
Cumulative USFDA approvals now stand at 235 (216 final and 19 tentative approvals)
👀 What to Watch
This approval is a positive development for Alembic's US generics business. Investors should monitor the company's product launch timeline and its ability to capture market share in the competitive CNS drug category.
